Terbutaline sustained-release treatment during one week 5 mg b.i.d. compared to one week placebo: terbutaline plasma levels, c-AMP plasma levels, lung function and tremor measurement.
In a group of ten patients with chronic asthmatic bronchitis, a good improvement of the lung function was achieved by a sustained-release terbutaline preparation (Bricanyl Retard) in a dosage of 5 mg twice daily. Tremor measurements and c-AMP plasma level showed a statistically significant increase. A good patient compliance was achieved with this dosage of terbutaline two times daily. The sustained-release preparation caused a rather constant and low terbutaline plasma level. We think that this relative low terbutaline plasma level is the most important reason for the lack of side effects.
van der Vet
A P
AP
Department of Pulmonology, University of Limburg, Maastricht, The Netherlands.
Kreukniet
J
J
Drost
R H
RH
Maes
R A
RA
Fokkens
J K
JK
Hamelink
M L
ML
D000328:Adult; D001991:Bronchitis / Q000188:drug therapy*; D000242:Cyclic AMP / Q000097:blood; D003692:Delayed-Action Preparations; D005260:Female; D005541:Forced Expiratory Volume; D006801:Humans; D008297:Male; D008875:Middle Aged; D013726:Terbutaline / Q000008:administration & dosage* / Q000097:blood*; D014202:Tremor / Q000139:chemically induced*; D014797:Vital Capacity / Q000187:drug effects*
D003692:Delayed-Action Preparations; D000242:Cyclic AMP; D013726:Terbutaline